A city is experiencing an active flu season dominated by the H3 subtype of influenza A, similar to the previous year. The season is defying typical patterns, having extended from the previous year, and is expected to remain active through August and September, with vaccines noted as effective.
US health advisers are reviewing Moderna's new mRNA flu vaccine, mFlusiva, for individuals 50 and older. The vaccine, similar to those used for COVID-19, showed a 27% reduction in flu cases in a study. The FDA is assessing its safety and efficacy, with a decision expected before the winter flu season.
Hong Kong's Centre for Health Protection anticipates an earlier summer flu season, with a potential peak in late June or July. This is due to increased influenza activity since May and the absence of a typical winter flu season, which may lead to lower public immunity and higher transmission rates.
